topotecan has been researched along with Emesis in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Acosta, G; Fiani, B; Haynes, M; Nikolaidis, D; Rose, A; Runnels, J; Wong, A | 1 |
| Bodnar, L; Gasowska-Bodnar, A; Nasilowska, A; Smoter, M; Szarlej-Wcislo, K; Szczylik, C; Wcislo, G | 1 |
| Holcombe, RF; Kong, KM; Wimmer, D | 1 |
| Curtin, JP; Dellenbaugh, C; Hamilton, A; Hochster, H; Lee, S; Liebes, L; Mirchandani, D; Muggia, FM; Sorich, J; Yee, H | 1 |
| Gajra, A; Garziano, S; Kirshner, J; Neuman, N; Perry, M; Ready, N; Shah, C | 1 |
| Bonneterre, J | 1 |
| Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR | 1 |
| Beijnen, JH; Herben, VM; Hudson, I; Schot, ME; ten Bokkel Huinink, WW | 1 |
| Abbruzzese, JL; Ellis, AL; Hess, KR; Loughlin, S; Madden, T; Newman, RA; Raber, MN; Sugarman, SM; Zwelling, LA | 1 |
| Anderson, H; Carrington, B; Cheeseman, S; Hearn, S; Ranson, M; Ross, G; Thatcher, N; White, SC | 1 |
| de Jonge, MJ; Gelderblom, H; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| Dubuc-Lissoir, J; Eisenhauer, E; Fisher, B; Grimshaw, R; Hoskins, P; Oza, A; Plante, M; Stuart, G; Vergote, I; Vermorken, J | 1 |
| Beckman, RA; Gore, M; Hearn, S; Lane, SR; Ross, G; Rustin, G; Schüller, J | 1 |
| Aalders, JG; Beijnen, JH; Bos, AM; de Vries, EG; Hofstra, LS; Mulder, NH; Rosing, H; van der Zee, AG; Willemse, PH | 1 |
2 review(s) available for topotecan and Emesis
| Article | Year |
|---|---|
The role for intra-arterial chemotherapy for refractory retinoblastoma: a systematic review.
Topics: Antineoplastic Agents; Bronchial Spasm; Carboplatin; Drug Resistance, Neoplasm; Edema; Eyelashes; Febrile Neutropenia; Humans; Infusions, Intra-Arterial; Melphalan; Methotrexate; Nausea; Retinal Neoplasms; Retinoblastoma; Salvage Therapy; Topotecan; Vitreous Hemorrhage; Vomiting | 2021 |
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting | 1995 |
12 trial(s) available for topotecan and Emesis
| Article | Year |
|---|---|
Salvage therapy with topotecan in heavily pretreated ovarian cancer patients.
Topics: Alopecia; Anemia; Antineoplastic Agents; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Ovarian Neoplasms; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome; Vomiting | 2009 |
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting | 2004 |
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liposomes; Male; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome; Vomiting | 2005 |
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan; Vomiting | 2007 |
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting | 1997 |
Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Biomarkers; Carcinoma, Small Cell; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting | 1998 |
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Headache; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Skin Diseases; Thrombocytopenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome; Vomiting | 1996 |
Phase II study of oral topotecan in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting | 2000 |
Topotecan lacks third space sequestration.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ascitic Fluid; Cisplatin; Dexamethasone; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Ondansetron; Pleural Effusion; Topotecan; Vomiting | 2000 |
Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epithelium; Feasibility Studies; Female; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Rate; Topotecan; Vomiting | 2000 |
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
Topics: Abdominal Pain; Adult; Aged; Alopecia; Antineoplastic Agents; Diarrhea; Fatigue; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Nausea; Ovarian Neoplasms; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome; Vomiting | 2001 |
A phase I and pharmacokinetic study of intraperitoneal topotecan.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Exanthema; Fatigue; Female; Humans; Injections, Intraperitoneal; Metabolic Clearance Rate; Middle Aged; Nausea; Ovarian Neoplasms; Topotecan; Treatment Outcome; Vomiting | 2001 |